Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lin Li, Yuwei Zhang, Yudan Luo, Xianghui Meng, Guixiang Pan, Han Zhang, Yuhong Li & Boli Zhang. (2023) The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications. Drug Design, Development and Therapy 17, pages 771-790.
Read now
Read now
Xiaoju Ma, Jingru Ma, Tian Leng, Zhongzhu Yuan, Tingting Hu, Qiuyan Liu & Tao Shen. (2023) Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention. Renal Failure 45:1.
Read now
Read now
Noori Al-Waili, Hamza Al-Waili, Thia Al-Waili & Khelod Salom. (2017) Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials. Redox Report 22:3, pages 99-118.
Read now
Read now
Articles from other publishers (22)
Siqi Qin, Junren Chen, Kexin Zhong, Dan Li & Cheng Peng. (2023) Could Cyclosiversioside F Serve as a Dietary Supplement to Prevent Obesity and Relevant Disorders?. International Journal of Molecular Sciences 24:18, pages 13762.
Crossref
Crossref
Yiwei Gao, Xin Su, Taiqi Xue & Ning Zhang. (2023) The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease. Biomedicine & Pharmacotherapy 163, pages 114598.
Crossref
Crossref
Liping Cao, Jinliang Du, Rui Jia, Jiancao Gao, Zhijuan Nie, Nailin Shao, Quanjie Li, Haojun Zhu, Guojun Yin, Weidong Ding & Gangchun Xu. (2023) Alleviative effects of astragaloside IV on cyclophosphamide-induced oxidative damage and immunosuppression in tilapia (Oreochromis niloticus). Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 264, pages 109503.
Crossref
Crossref
Lumin Tang, Xiang Li, Yu Qin, Xinyao Geng, Ruowen Wang, Weihong Tan & Shan Mou. (2022) The construction of oligonucleotide-cycloastragenol and the renoprotective effect study. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Meixia Feng, Juan Lv, Chenxi Zhang, Dagui Chen, Huan Guo, Ye Tu, Li Su & Zhibin Wang. (2022) Astragaloside IV Protects Sepsis-induced Acute Kidney Injury by Attenuating Mitochondrial
Dysfunction and Apoptosis in Renal Tubular Epithelial Cells. Current Pharmaceutical Design 28:34, pages 2825-2834.
Crossref
Crossref
Yunlai Wang, Ye Feng, Manman Li, Mo Yang, Gaoxiang Shi, Zihua Xuan, Dengke Yin & Fan Xu. (2022) Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms. Frontiers in Pharmacology 13.
Crossref
Crossref
Yue Qiu, Yang Qiu, Guang-Min Yao, Changqing Luo & Chun Zhang. (2022) Natural product therapies in chronic kidney diseases: An update. Néphrologie & Thérapeutique 18:2, pages 75-79.
Crossref
Crossref
Yaji Dai, Mingfei Guo, Lei Jiang & Jiarong Gao. (2022) Network pharmacology-based identification of miRNA expression of Astragalus membranaceus in the treatment of diabetic nephropathy. Medicine 101:5, pages e28747.
Crossref
Crossref
Xingchi Kan, Juxiong Liu, Yingsheng Chen, Wenjin Guo, Dianwen Xu, Ji Cheng, Yu Cao, Zhanqing Yang & Shoupeng Fu. (2021) Protective effect of myricetin on LPS-induced mastitis in mice through ERK1/2 and p38 protein author. Naunyn-Schmiedeberg's Archives of Pharmacology 394:8, pages 1727-1735.
Crossref
Crossref
Mingming Zhao, Yi Yu, Rumeng Wang, Meiying Chang, Sijia Ma, Hua Qu & Yu Zhang. (2021) Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease. Frontiers in Pharmacology 11.
Crossref
Crossref
Dong Han. (2021) Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats. Journal of International Medical Research 49:3, pages 030006051984116.
Crossref
Crossref
Qingqing Chen, Yong Su, Yinghui Ju, Keke Ma, Weizu Li & Weiping Li. (2018) Astragalosides IV protected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis. Biomedicine & Pharmacotherapy 108, pages 679-686.
Crossref
Crossref
Sha Di, Lin Han, Qing Wang, Xinkui Liu, Yingying Yang, Fan Li, Linhua Zhao & Xiaolin Tong. (2018) A Network Pharmacology Approach to Uncover the Mechanisms of Shen-Qi-Di-Huang Decoction against Diabetic Nephropathy. Evidence-Based Complementary and Alternative Medicine 2018, pages 1-14.
Crossref
Crossref
Gaofeng Song, Pengxun Han, Huili Sun, Mumin Shao, Xuewen Yu, Wenjing Wang, Dongtao Wang, Wuyong Yi, Na Ge, Shunmin Li & Tiegang Yi. (2018) Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. Journal of International Medical Research 46:7, pages 2883-2897.
Crossref
Crossref
Jun Li, Yuka Harata-Lee, Matthew D Denton, Qianjin Feng, Judith R Rathjen, Zhipeng Qu & David L Adelson. (2017) Long read reference genome-free reconstruction of a full-length transcriptome from Astragalus membranaceus reveals transcript variants involved in bioactive compound biosynthesis. Cell Discovery 3:1.
Crossref
Crossref
Lei Li, Xiaojiao Hou, Rongfang Xu, Chang Liu & Menbayaer Tu. (2017) Research review on the pharmacological effects of astragaloside IV. Fundamental & Clinical Pharmacology 31:1, pages 17-36.
Crossref
Crossref
Guang-dong Sun, Chao-yuan Li, Wen-peng Cui, Qiao-yan Guo, Chang-qing Dong, Hong-bin Zou, Shu-jun Liu, Wen-peng Dong & Li-ning Miao. (2016) Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy. Journal of Diabetes Research 2016, pages 1-18.
Crossref
Crossref
Yumin Wen, Yongli Zhan, Huijie Liu, Tingting Zhao, Liping Yang, Haojun Zhang, Xi Dong & Ping Li. (2015) Yi Qi Qing Re Gao formula ameliorates puromycin aminonucleoside-induced nephrosis by suppressing inflammation and apoptosis. BMC Complementary and Alternative Medicine 15:1.
Crossref
Crossref
Haijiang Wu, Yonghong Shi, Xinna Deng, Ye Su, Chunyang Du, Jinying Wei, Yunzhuo Ren, Ming Wu, Yanjuan Hou & Huijun Duan. (2015) Inhibition of c-Src/p38 MAPK pathway ameliorates renal tubular epithelial cells apoptosis in db/db mice. Molecular and Cellular Endocrinology 417, pages 27-35.
Crossref
Crossref
MINGJUN LI, WENGANG WANG, LI GENG, YANRU QIN, WENJIE DONG, XUDONG ZHANG, AN QIN & MINGZHI ZHANG. (2015) Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. International Journal of Molecular Medicine 36:5, pages 1335-1344.
Crossref
Crossref
Yifei Zhong, Madhav C. Menon, Yueyi Deng, Yiping Chen & John Cijiang He. (2015) Recent Advances in Traditional Chinese Medicine for Kidney Disease. American Journal of Kidney Diseases 66:3, pages 513-522.
Crossref
Crossref
Weijia Xu, Xinghua Shao, Lei Tian, Leyi Gu, Minfang Zhang, Qin Wang, Bei Wu, Ling Wang, Jufang Yao, Xiaoping Xu, Shan Mou & Zhaohui Ni. (2014) Astragaloside IV Ameliorates Renal Fibrosis via the Inhibition of Mitogen-Activated Protein Kinases and Antiapoptosis In Vivo and In Vitro. Journal of Pharmacology and Experimental Therapeutics 350:3, pages 552-562.
Crossref
Crossref